Micro regional heterogeneity of 64Cu-ATSM and 18F-FDG uptake in canine soft tissue sarcomas: Relation to cell proliferation, hypoxia and glycolysis

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Zornhagen, Kamilla Westarp ^a,b   Hansen, Anders E ^c   Oxboel, Jytte ^b   Clemmensen, Andreas E ^b   El Ali, Henrik H ^b   Kristensen, Annemarie T ^a   Kjaer, Andreas ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONATE DEHYDRATASE IX; COPPER 64; COPPER DIACETYL BIS(N4 METHYLTHIOSEMICARBAZONE) CU 64; FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KI 67 ANTIGEN; THROMBOPLASTIN; UNCLASSIFIED DRUG; VASCULOTROPIN A; COPPER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CAIX GENE; CANCER PROGNOSIS; CANINE MODEL; CARCINOGENESIS; CONTROLLED STUDY; CORRELATIONAL STUDY; GENE; GENE EXPRESSION; GLUT1 GENE; GLUT3 GENE; GLYCOLYSIS; HALF LIFE TIME; HIF 1ALPHA GENE; HISTOPATHOLOGY; HK2 GENE; HYPOXIA; IMMUNOHISTOCHEMISTRY; KI 67 GENE; NONHUMAN; PROSPECTIVE STUDY; RADIOACTIVITY; SOFT TISSUE SARCOMA; TF GENE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR SCINTISCANNING; VEGFA GENE; ANIMAL; CELL PROLIFERATION; DOG; PATHOPHYSIOLOGY; PHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; SARCOMA;

ANIMALS; CELL PROLIFERATION; COPPER RADIOISOTOPES; DOGS; FLUORODEOXYGLUCOSE F18; GLYCOLYSIS; HYPOXIA; POSITRON-EMISSION TOMOGRAPHY; SARCOMA;

EID: 84949254795     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0141379     Document Type: Article

References (79)

1. Poste G, Greig R. The experimental and clinical implications of cellular heterogeneity in malignant tumors. Journal of Cancer Reseach and Clinical Oncology. 1983; 106(3): 159-70. Epub 1983/01/01. PMID: 6654949.
2. Heppner GH. Tumor heterogeneity. Cancer Res. 1984; 44(6): 2259-65. Epub 1984/06/01. PMID: 6372991.
3. Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: A looking glass for cancer? Nat Rev Cancer. 2012; 12(5): 323-34. Epub 2012/04/20. doi: 10.1038/nrc3261 PMID: 22513401.
4. van Kempen LC, Ruiter DJ, van Muijen GN, Coussens LM. The tumor microenvironment: A critical determinant of neoplastic evolution. European journal of cell biology. 2003; 82(11): 539-48. Epub 2004/01/02. doi: 10.1078/0171-9335-00346 PMID: 14703010.
5. Egeblad M, Nakasone ES, Werb Z. Tumors as organs: Complex tissues that interface with the entire organism. Developmental cell. 2010; 18(6): 884-901. Epub 2010/07/16. doi: 10.1016/j.devcel.2010.05. 012 PMID: 20627072; PubMed Central PMCID: PMC2905377.
6. Weber CE, Kuo PC. The tumor microenvironment. Surgical oncology. 2012; 21(3): 172-7. Epub 2011/10/04. doi: 10.1016/j.suronc.2011.09.001 PMID: 21963199.
7. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100(1): 57-70. Epub 2000/01/27. PMID: 10647931.
8. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011; 144(5): 646-74. Epub 2011/03/08. doi: 10.1016/j.cell.2011.02.013 PMID: 21376230.
9. Diaz-Cano SJ. General morphological and biological features of neoplasms: Integration of molecular findings. Histopathology. 2008; 53(1): 1-19. Epub 2008/02/20. doi: 10.1111/j.1365-2559.2007.02937.x PMID: 18282144.
10. Hanahan D, Coussens LM. Accessories to the crime: Functions of cells recruited to the tumor microenvironment. Cancer cell. 2012; 21(3): 309-22. Epub 2012/03/24. doi: 10.1016/j.ccr.2012.02.022 PMID: 22439926.
11. Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013; 501(7467): 346-54. Epub 2013/09/21. doi: 10.1038/nature12626 PMID: 24048067.
12. Warburg O. On the origin of cancer cells. Science. 1956; 123(3191): 309-14. Epub 1956/02/24. PMID: 13298683.
13. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science. 2009; 324(5930): 1029-33. Epub 2009/05/23. doi: 10.1126/science.1160809 PMID: 19460998; PubMed Central PMCID: PMC2849637.
14. Lopez-Lazaro M. The warburg effect: Why and how do cancer cells activate glycolysis in the presence of oxygen? Anticancer Agents Med Chem. 2008; 8(3): 305-12. Epub 2008/04/09. PMID: 18393789.
15. Vaupel P, Harrison L. Tumor hypoxia: Causative factors, compensatory mechanisms, and cellular response. The oncologist. 2004; 9 Suppl 5: 4-9. Epub 2004/12/14. doi: 10.1634/theoncologist.9-90005- 4 PMID: 15591417.
16. Grote J, Susskind R, Vaupel P. Oxygen diffusivity in tumor tissue (DS-carcinosarcoma) under temperature conditions within the range of 20-40 degrees C. Pflugers Arch. 1977; 372(1): 37-42. Epub 1977/11/25. PMID: 563582.
17. Harris AL. Hypoxia-A key regulatory factor in tumour growth. Nat Rev Cancer. 2002; 2(1): 38-47. Epub 2002/03/21. doi: 10.1038/nrc704 PMID: 11902584.
18. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000; 407(6801): 249-57. Epub 2000/09/23. doi: 10.1038/35025220 PMID: 11001068.
19. Semenza GL. HIF-1 and tumor progression: Pathophysiology and therapeutics. Trends Mol Med. 2002; 8(4 Suppl): S62-7. Epub 2002/04/03. PMID: 11927290.
20. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004; 4 (11): 891-9. Epub 2004/11/02. doi: 10.1038/nrc1478 PMID: 15516961.
21. Walenta S, Mueller-Klieser WF. Lactate: Mirror and motor of tumor malignancy. Seminars in radiation oncology. 2004; 14(3): 267-74. Epub 2004/07/16. doi: 10.1016/j.semradonc.2004.04.004 PMID: 15254870.
22. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 1996; 379(6560): 88-91. Epub 1996/01/04. doi: 10.1038/379088a0 PMID: 8538748.
23. Reynolds TY, Rockwell S, Glazer PM. Genetic instability induced by the tumor microenvironment. Cancer Res. 1996; 56(24): 5754-7. Epub 1996/12/15. PMID: 8971187.
24. Brown JM, Giaccia AJ. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Res. 1998; 58(7): 1408-16. Epub 1998/04/16. PMID: 9537241.
25. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 1996; 56 (5): 941-3. Epub 1996/03/01. PMID: 8640781.
26. Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol. 2005; 77(1): 18-24. Epub 2005/08/16. doi: 10.1016/j.radonc.2005.06.038 PMID: 16098619.
27. Dehdashti F, Grigsby PW, Lewis JS, Laforest R, Siegel BA, Welch MJ. Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med. 2008; 49(2): 201-5. Epub 2008/01/18. doi: 10.2967/jnumed.107.048520 PMID: 18199612.
28. Xie P, Li M, Zhao H, Sun X, Fu Z, Yu J. 18F-FDG PET or PET-CT to evaluate prognosis for head and neck cancer: A meta-analysis. Journal of Cancer Reseach and Clinical Oncology. 2011; 137(7): 1085-93. Epub 2011/01/14. doi: 10.1007/s00432-010-0972-y PMID: 21229262.
29. Zhang H, Wroblewski K, Liao S, Kampalath R, Penney BC, Zhang Y, et al. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer. Academic radiology. 2013; 20(1): 32-40. Epub 2012/09/25. doi: 10.1016/j.acra.2012.07.002 PMID: 22999369.
30. van Diest PJ, Brugal G, Baak JP. Proliferation markers in tumours: Interpretation and clinical value. Journal of clinical pathology. 1998; 51(10): 716-24. Epub 1999/02/19. doi: 10.1136/jcp.51.10.716 PMID: 10023332; PubMed Central PMCID: PMC500923.
31. Campos M, SG DEC, Ribeiro GG, Eguchi FC, Silva SR, CZ DEO, et al. Ki-67 and CD100 immunohistochemical expression is associated with local recurrence and poor prognosis in soft tissue sarcomas, respectively. Oncol Lett. 2013; 5(5): 1527-35. Epub 2013/06/14. doi: 10.3892/ol.2013.1226 PMID: 23759874; PubMed Central PMCID: PMC3678859.
32. Clavo AC, Brown RS, Wahl RL. Fluorodeoxyglucose Uptake in Human Cancer Cell-Lines Is Increased by Hypoxia. Journal of Nuclear Medicine. 1995; 36(9): 1625-32. PMID: WOS: A1995RU09500027.
33. Lohith TG, Kudo T, Demura Y, Umeda Y, Kiyono Y, Fujibayashi Y, et al. Pathophysiologic correlation between 62Cu-ATSM and 18F-FDG in lung cancer. J Nucl Med. 2009; 50(12): 1948-53. Epub 2009/11/17. doi: 10.2967/jnumed.109.069021 PMID: 19910425.
34. Kositwattanarerk A, Oh M, Kudo T, Kiyono Y, Mori T, Kimura Y, et al. Different distribution of (62) Cu ATSM and (18)F-FDG in head and neck cancers. Clin Nucl Med. 2012; 37(3): 252-7. Epub 2012/02/09. doi: 10.1097/RLU.0b013e31823eaadb PMID: 22310251.
35. Busk M, Horsman MR, Jakobsen S, Bussink J, van der Kogel A, Overgaard J. Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage. Eur J Nucl Med Mol Imaging. 2008; 35 (12): 2294-303. Epub 2008/08/07. doi: 10.1007/s00259-008-0888-9 PMID: 18682937.
36. Christian N, Deheneffe S, Bol A, De Bast M, Labar D, Lee JA, et al. Is (18)F-FDG a surrogate tracer to measure tumor hypoxia? Comparison with the hypoxic tracer (14)C-EF3 in animal tumor models. Radiother Oncol. 2010; 97(2): 183-8. Epub 2010/03/23. doi: 10.1016/j.radonc.2010.02.020 PMID: 20304513.
37. Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: A new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med. 1997; 38 (7): 1155-60. Epub 1997/07/01. PMID: 9225812.
38. Lewis JS, Laforest R, Dehdashti F, Grigsby PW, Welch MJ, Siegel BA. An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix. J Nucl Med. 2008; 49(7): 1177-82. Epub 2008/06/17. doi: 10.2967/jnumed.108.051326 PMID: 18552145; PubMed Central PMCID: PMC4412029.
39. Hansen AE, Kristensen AT, Law I, McEvoy FJ, Kjaer A, Engelholm SA. Multimodality functional imaging of spontaneous canine tumors using 64Cu-ATSM and 18FDG PET/CT and dynamic contrast enhanced perfusion CT. Radiother Oncol. 2012; 102(3): 424-8. Epub 2011/11/29. doi: 10.1016/j.radonc.2011.10. 021 PMID: 22119225.
40. Grassi I, Nanni C, Cicoria G, Blasi C, Bunkheila F, Lopci E, et al. Usefulness of 64Cu-ATSM in head and neck cancer: A preliminary prospective study. Clin Nucl Med. 2014; 39(1): E59-63. Epub 2013/10/08. doi: 10.1097/RLU.0b013e3182a756f0 PMID: 24097008.
41. Tanaka T, Furukawa T, Fujieda S, Kasamatsu S, Yonekura Y, Fujibayashi Y. Double-tracer autoradiography with Cu-ATSM/FDG and immunohistochemical interpretation in four different mouse implanted tumor models. Nucl Med Biol. 2006; 33(6): 743-50. Epub 2006/08/29. doi: 10.1016/j.nucmedbio.2006. 05.005 PMID: 16934693.
42. Oh M, Tanaka T, Kobayashi M, Furukawa T, Mori T, Kudo T, et al. Radio-copper-labeled Cu-ATSM: An indicator of quiescent but clonogenic cells under mild hypoxia in a Lewis lung carcinoma model. Nucl Med Biol. 2009; 36(4): 419-26. Epub 2009/05/09. doi: 10.1016/j.nucmedbio.2009.01.016 PMID: 19423010.
43. Dence CS, Ponde DE, Welch MJ, Lewis JS. Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer. Nucl Med Biol. 2008; 35(6): 713-20. Epub 2008/08/06. doi: 10.1016/j.nucmedbio. 2008.06.001 PMID: 18678357; PubMed Central PMCID: PMC2661147.
44. Lewis JS, Sharp TL, Laforest R, Fujibayashi Y, Welch MJ. Tumor uptake of copper-diacetyl-bis(N(4)- methylthiosemicarbazone): Effect of changes in tissue oxygenation. J Nucl Med. 2001; 42(4): 655-61. Epub 2001/05/05. PMID: 11337556.
45. Obata A, Yoshimoto M, Kasamatsu S, Naiki H, Takamatsu S, Kashikura K, et al. Intra-tumoral distribution of (64)Cu-ATSM: A comparison study with FDG. Nucl Med Biol. 2003; 30(5): 529-34. Epub 2003/07/02. doi: 10.1016/s0969-8051(03)00047-7 PMID: 12831991.
46. Busk M, Toustrup K, Sorensen BS, Alsner J, Horsman MR, Jakobsen S, et al. In vivo identification and specificity assessment of mRNA markers of hypoxia in human and mouse tumors. BMC cancer. 2011; 11: 63. Epub 2011/02/11. doi: 10.1186/1471-2407-11-63 PMID: 21306648; PubMed Central PMCID: PMC3042974.
47. Boellaard R, O'Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: Version 1.0. Eur J Nucl Med Mol Imaging. 2010; 37(1): 181-200. Epub 2009/11/17. doi: 10.1007/s00259-009-1297-4 PMID: 19915839; PubMed Central PMCID: PMC2791475.
48. Acton PD, Zhuang H, Alavi A. Quantification in PET. Radiol Clin North Am. 2004; 42(6): 1055-62, viii. Epub 2004/10/19. doi: 10.1016/j.rcl.2004.08.010 PMID: 15488557.
49. Fleige S, Pfaffl MW. RNA integrity and the effect on the real-time qRT-PCR performance. Mol Aspects Med. 2006; 27(2-3): 126-39. Epub 2006/02/14. doi: 10.1016/j.mam.2005.12.003 PMID: 16469371.
50. Zornhagen KW, Kristensen AT, Hansen AE, Oxboel J, Kjaer A. Selection of suitable reference genes for normalization of genes of interest in canine soft tissue sarcomas using quantitative real-time polymerase chain reaction. Vet Comp Oncol. 2014. Epub 2014/07/06. doi: 10.1111/vco.12108 PMID: 24995963.
51. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: Minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009; 55 (4): 611-22. Epub 2009/02/28. doi: 10.1373/clinchem.2008.112797 PMID: 19246619.
52. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome biology. 2002; 3(7): RESEARCH0034. Epub 2002/08/20. PMID: 12184808; PubMed Central PMCID: PMC126239.
53. Hellemans J, Mortier G, De Paepe A, Speleman F, Vandesompele J. qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome biology. 2007; 8(2): R19. Epub 2007/02/13. doi: 10.1186/gb-2007-8-2-r19 PMID: 17291332; PubMed Central PMCID: PMC1852402.
54. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25(4): 402-8. Epub 2002/02/16. doi: 10.1006/meth.2001.1262 PMID: 11846609.
55. Hansen AE, Kristensen AT, Jorgensen JT, McEvoy FJ, Busk M, van der Kogel AJ, et al. (64)Cu-ATSM and (18)FDG PET uptake and (64)Cu-ATSM autoradiography in spontaneous canine tumors: Comparison with pimonidazole hypoxia immunohistochemistry. Radiat Oncol. 2012; 7: 89. Epub 2012/06/19. doi: 10.1186/1748-717X-7-89 PMID: 22704363; PubMed Central PMCID: PMC3403947.
56. Bradshaw TJ, Bowen SR, Jallow N, Forrest LJ, Jeraj R. Heterogeneity in intratumor correlations of 18FFDG, 18F-FLT, and 61Cu-ATSM PET in canine sinonasal tumors. J Nucl Med. 2013; 54(11): 1931-7. Epub 2013/09/18. doi: 10.2967/jnumed.113.121921 PMID: 24042031; PubMed Central PMCID: PMC3974156.
57. Yuan H, Schroeder T, Bowsher JE, Hedlund LW, Wong T, Dewhirst MW. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med. 2006; 47(6): 989-98. Epub 2006/06/03. PMID: 16741309.
58. Clausen MM, Hansen AE, Lundemann M, Hollensen C, Pommer T, Munck Af Rosenschold P, et al. Dose painting based on tumor uptake of Cu-ATSM and FDG: A comparative study. Radiat Oncol. 2014; 9(1): 228. Epub 2014/10/17. doi: 10.1186/s13014-014-0228-0 PMID: 25319766; PubMed Central PMCID: PMC4203925.
59. Yamamoto T, Seino Y, Fukumoto H, Koh G, Yano H, Inagaki N, et al. Over-expression of facilitative glucose transporter genes in human cancer. Biochemical and biophysical research communications. 1990; 170(1): 223-30. Epub 1990/07/16. PMID: 2372287.
60. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. Journal of cellular physiology. 2005; 202(3): 654-62. Epub 2004/09/25. doi: 10.1002/jcp.20166 PMID: 15389572.
61. Krzeslak A, Wojcik-Krowiranda K, Forma E, Jozwiak P, Romanowicz H, Bienkiewicz A, et al. Expression of GLUT1 and GLUT3 glucose transporters in endometrial and breast cancers. Pathology oncology research: POR. 2012; 18(3): 721-8. Epub 2012/01/25. doi: 10.1007/s12253-012-9500-5 PMID: 22270867; PubMed Central PMCID: PMC3342495.
62. Simpson IA, Dwyer D, Malide D, Moley KH, Travis A, Vannucci SJ. The facilitative glucose transporter GLUT3: 20 years of distinction. American journal of physiology Endocrinology and metabolism. 2008; 295(2): E242-53. Epub 2008/06/26. doi: 10.1152/ajpendo.90388.2008 PMID: 18577699; PubMed Central PMCID: PMC2519757.
63. Marin-Hernandez A, Gallardo-Perez JC, Ralph SJ, Rodriguez-Enriquez S, Moreno-Sanchez R. HIF- 1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. Mini Rev Med Chem. 2009; 9(9): 1084-101. Epub 2009/08/20. PMID: 19689405.
64. Semenza GL. HIF-1: Upstream and downstream of cancer metabolism. Curr Opin Genet Dev. 2010; 20 (1): 51-6. Epub 2009/11/28. doi: 10.1016/j.gde.2009.10.009 PMID: 19942427; PubMed Central PMCID: PMC2822127.
65. Hansen AE, Kristensen AT, Law I, Jorgensen JT, Engelholm SA. Hypoxia-inducible factors-regulation, role and comparative aspects in tumourigenesis. Vet Comp Oncol. 2011; 9(1): 16-37. Epub 2011/02/10. doi: 10.1111/j.1476-5829.2010.00233.x PMID: 21303451.
66. Semenza GL. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annual review of cell and developmental biology. 1999; 15: 551-78. Epub 1999/12/28. doi: 10.1146/annurev.cellbio. 15.1.551 PMID: 10611972.
67. Chen C, Pore N, Behrooz A, Ismail-Beigi F, Maity A. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. The Journal of biological chemistry. 2001; 276 (12): 9519-25. Epub 2000/12/30. doi: 10.1074/jbc.M010144200 PMID: 11120745.
68. Dery MA, Michaud MD, Richard DE. Hypoxia-inducible factor 1: Regulation by hypoxic and non-hypoxic activators. The international journal of biochemistry & cell biology. 2005; 37(3): 535-40. Epub 2004/12/25. doi: 10.1016/j.biocel.2004.08.012 PMID: 15618010.
69. Bardos JI, Ashcroft M. Hypoxia-inducible factor-1 and oncogenic signalling. BioEssays: News and reviews in molecular, cellular and developmental biology. 2004; 26(3): 262-9. Epub 2004/02/28. doi: 10.1002/bies.20002 PMID: 14988927.
70. Lehmann S, Stiehl DP, Honer M, Dominietto M, Keist R, Kotevic I, et al. Longitudinal and multimodal in vivo imaging of tumor hypoxia and its downstream molecular events. Proc Natl Acad Sci U S A. 2009; 106(33): 14004-9. Epub 2009/08/12. doi: 10.1073/pnas.0901194106 PMID: 19666490; PubMed Central PMCID: PMC2729010.
71. Sorensen BS, Hao J, Overgaard J, Vorum H, Honore B, Alsner J, et al. Influence of oxygen concentration and pH on expression of hypoxia induced genes. Radiother Oncol. 2005; 76(2): 187-93. Epub 2005/08/16. doi: 10.1016/j.radonc.2005.06.037 PMID: 16098620.
72. Mayer A, Hockel M, Vaupel P. Carbonic anhydrase IX expression and tumor oxygenation status do not correlate at the microregional level in locally advanced cancers of the uterine cervix. Clin Cancer Res. 2005; 11(20): 7220-5. Epub 2005/10/26. doi: 10.1158/1078-0432.CCR-05-0869 PMID: 16243791.
73. Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell. 2014; 158 (4): 929-44. Epub 2014/08/12. doi: 10.1016/j.cell.2014.06.049 PMID: 25109877; PubMed Central PMCID: PMC4152462.
74. Shou Y, Lu J, Chen T, Ma D, Tong L. Correlation of fluorodeoxyglucose uptake and tumor-proliferating antigen Ki-67 in lymphomas. Journal of cancer research and therapeutics. 2012; 8(1): 96-102. Epub 2012/04/26. doi: 10.4103/0973-1482.95182 PMID: 22531522.
75. Vesselle H, Salskov A, Turcotte E, Wiens L, Schmidt R, Jordan CD, et al. Relationship between nonsmall cell lung cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index. J Thorac Oncol. 2008; 3(9): 971-8. Epub 2008/09/02. doi: 10.1097/JTO.0b013e31818307a7 PMID: 18758298.
76. Han B, Lin S, Yu LJ, Wang RZ, Wang YY. Correlation of (1)(8)F-FDG PET activity with expressions of survivin, Ki67, and CD34 in non-small-cell lung cancer. Nucl Med Commun. 2009; 30(11): 831-7. Epub 2009/09/08. doi: 10.1097/MNM.0b013e32832dcfc4 PMID: 19734817.
77. Folpe AL, Lyles RH, Sprouse JT, Conrad EU 3rd, Eary JF. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res. 2000; 6(4): 1279-87. Epub 2000/04/25. PMID: 10778952.
78. Park SG, Lee JH, Lee WA, Han KM. Biologic correlation between glucose transporters, hexokinase-II, Ki-67 and FDG uptake in malignant melanoma. Nucl Med Biol. 2012; 39(8): 1167-72. Epub 2012/08/21. doi: 10.1016/j.nucmedbio.2012.07.003 PMID: 22901702.
79. Engelmann BE, Binderup T, Kjaer A, Loft A, Gerds TA, Berthelsen AK, et al. Quantitative gene expression underlying 18f-fluorodeoxyglucose uptake in colon cancer. Journal of Clinical Oncology. 2015; 33 (3 suppl): Abstract 653.